The ODAC cited concerns with patient populations in clinical trials used to support the proposed expansion. Johnson & Johnson ...

US biotech IGM Biosciences (Nasdaq: IGMS), which is developing and delivering medicines to treat patients with autoimmune and ...

B-cell therapy for multiple sclerosis (MS) was first approved in 2017, after the anti-CD20 agent ocrelizumab (Ocrevus) demonstrated its ability to strongly suppress the acute inflammatory activity ...

WORCESTER COUNTY, Md. -- Ocean City leaders got some promising news at a Tuesday, April 29 work session. The project to widen Route 90 is back on the state of Maryland's agenda. Environmental ...

The approval targets patients who have undergone a minimum of three previous therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cluster of differentiation 38 (CD38) ...

CD27 and CD40 costimulatory molecules and TILs expressing activation marker CD38 in the tumour were also correlated with ... value of densities of tumour-infiltrating CD3 + T cells and CD20 + B cells ...

The AURIGA study evaluated treatment responses among 200 patients with newly diagnosed multiple myeloma who experienced very good or better partial responses, were MRD-positive and anti-CD38-naïve ...

In this report, we describe two cases of juvenile-onset refractory LN/SLE successfully managed with a combination of a single infusion of rituximab (targeting CD20 on B cells) and daratumumab ...

The first dose of KJ-C2320, an allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD38, has been administered to a patient ... which targets CD19 and CD20, for the treatment of B-cell ...

The business is stopping further research on imvotamab, a CD20 x CD3 bispecific antibody, and IGM-2644, a CD38 x CD3 bispecific antibody. Phase 1b rheumatoid arthritis and systemic lupus ...